Kinase Inhibitors Market By Product 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Kinase Inhibitors Market
Kinase Inhibitors Market: By Product (Angiogenesis, m-TOR, BRAF and MEK, Bcr-Abl Tyrosine-Kinase (TKI), EGFR, PI3K, Aurora-Kinase Inhibitors, & Others), By End-User (Hospitals, Research Labs, & Others) & By Region-Forecast (2016-2021)
Report Code : HCR 0236
Published: 03 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Kinase inhibitors are enzymes which selectively block the action of other enzymes, and help in regulation of the activity of other proteins and, the activities of cells. Globally, growing focus of pharmaceutical companies on R&D to come up with potential medicines for treatment of cancers, rise in the in aging population, and increasing incidence and frequency of various cancers are the prime growth drivers of global kinase inhibitors market. In addition, increase in adoption of kinase inhibitors for newer applications, and emerging economies such as China, India and others, will create new opportunities for global kinase inhibitors market. However, The research and development having higher cost, complex approvals processes, and stringent government policies are the key restraints for global kinase inhibitors market.

This report identifies the global kinase inhibitors market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global kinase inhibitors market.
 
Kinase Inhibitors Market

Geographically North America dominated global kinase inhibitors market, and Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population, growing incidence and prevalence of cancer patients and modernizing healthcare infrastructure in the developing nations such as China, and India in this region. Among all the end-users, hospital segment has the highest market share in global kinase inhibitors market.

This report segments global kinase inhibitors market on the basis of product, end-user, and regional market as follows:
  • Kinase Inhibitors Market, By Product: Angiogenesis Inhibitors, m-TOR Inhibitors, BRAF and MEK Inhibitors, Bcr-Abl Tyrosine-Kinase Inhibitors (TKI), EGFR Inhibitors, PI3K Inhibitors, Aurora-Kinase Inhibitors, and Others
  • The report has focused study on kinase inhibitors market by basis of end-user such as: Hospitals, Research Labs, and Others
  • This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the kinase inhibitors market. Some of the major companies’ profiles in detail are as follows:
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim GmbH
  • AstraZeneca, Eisai Co., Ltd.
  • Bristol-Myers Squibb
  • Glaxo SmithKline
1. Kinase Inhibitors Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Kinase Inhibitors Market– Market Forces
   4.1. Drivers
      4.1.1. Growing focus of pharmaceutical companies on R&D to come up with potential medicines for treatment of cancers
      4.1.2. Rise in the in aging population
      4.1.3. Increasing incidence and frequency of various cancers
   4.2. Restraints
      4.2.1. The research and development having higher cost
      4.2.2. Complex approvals processes
      4.2.3. Stringent government policies
   4.3. Opportunities
      4.3.1. Emerging economies
      4.3.2. Increase in adoption of kinase inhibitors for newer applications
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Kinase Inhibitors Market, By Product
   5.1. Angiogenesis Inhibitors
   5.2. m-TOR Inhibitors
   5.3. BRAF and MEK Inhibitors
   5.4. Bcr-Abl Tyrosine-Kinase Inhibitors (TKI)
   5.5. EGFR Inhibitors
   5.6. PI3K Inhibitors
   5.7. Aurora-Kinase Inhibitors
   5.8. Others
6. Kinase Inhibitors Market, By End-User
   6.1. Hospitals
   6.2. Research Labs
   6.3. Others
7. Kinase Inhibitors Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Kinase Inhibitors – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles
   9.1. Takeda Pharmaceutical Company Limited
   9.2. Boehringer Ingelheim GmbH
   9.3. AstraZeneca, Eisai Co., Ltd.
   9.4. Bristol-Myers Squibb
   9.5. Glaxo SmithKline
   9.6. Incyte Corporation
   9.7. Bayer AG
   9.8. Pfizer Inc.
   9.9. Eisai Co., Ltd.
   9.10. Novartis AG
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix

   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Expert Insights
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll